Evidence map›Paper›PMID 28383135›Full record

ArticleBritish journal of pharmacology2017

Transbody against virus core protein potently inhibits hepadnavirus replication in vivo: evidence from a duck model of hepatitis B virus.

Yiping Li, Zhengwen Liu, Lingyun Hui, Xi Liu, Ai Feng, Wei Wang, Lin Zhang, Na Li, Guoqing Zhou, Quanli Wang and 5 more

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of pharmacology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 46% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 4 institutions in 1 country.

Yiping LiSchool of Pharmacy, Xi'an Jiaotong University, Xi'an, China.
Zhengwen LiuDepartment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China.
Lingyun HuiDepartment of Laboratory Medicine, First Affiliated Hospital, School of medicine, Xi'an Jiaotong University, Xi'an, China.
Xi LiuDepartment of Pathology, First Affiliated Hospital, School of medicine, Xi'an Jiaotong University, Xi'an, China.
Ai FengDepartment of Laboratory Medicine, First Affiliated Hospital, School of medicine, Xi'an Jiaotong University, Xi'an, China.
Wei WangDepartment of Laboratory Medicine, First Affiliated Hospital, School of medicine, Xi'an Jiaotong University, Xi'an, China.
Lin ZhangDepartment of Laboratory Medicine, First Affiliated Hospital, School of medicine, Xi'an Jiaotong University, Xi'an, China.
Na LiDepartment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China.
Guoqing ZhouSchool of Computer Science and Engineering, Northwestern Polytechnical University, Xi'an, China.
Quanli WangDepartment of Epidemiology and Statistics, School of medicine, Xi'an Jiaotong University, Xi'an, China.
Qunying HanDepartment of Infectious Diseases, First Affiliated Hospital, School of Medicine, Xi'an Jiaotong University, Xi'an, China.
Yi LvInstitute of Advanced Surgical Technology and Engineering, Xi'an Jiaotong University, Xi'an, China.
Quanying WangXi'an Hua Guang Biological Engineering Company, Xi'an, China.
Guangxiao YangXi'an Hua Guang Biological Engineering Company, Xi'an, China.
Yawen WangDepartment of Laboratory Medicine, First Affiliated Hospital, School of medicine, Xi'an Jiaotong University, Xi'an, China.
First Affiliated Hospital of Xi'an Jiaotong University · CNXi'an Jiaotong University · CNChina XD Group (China) · CNNorthwestern Polytechnical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

background and purposeThe therapeutic management of hepatitis B virus (HBV) infections remains challenging, and novel antiviral strategies are urgently required. The HBV transbody, a monoclonal antibody (MAb) against human HBcAg coupled with the trans-activator of transcription protein transduction domain (TAT PTD), was previously shown to possess cell-penetrating ability and potent antiviral activity in vitro. The purpose of the present study was to evaluate the antiviral activity of the HBcMAb-TAT PTD conjugate in vivo in a duck model of HBV. EXPERIMENTAL APPROACH: Female Peking ducks were injected i.p. with 0.03-0.3 mg·kg KEY

resultsThe DHBV transbody significantly reduced the serum and liver DHBV DNA levels at doses of 0.1 and 0.3 mg·kg CONCLUSIONS AND IMPLICATIONS: The DHBV transbody inhibits DHBV replication and possesses potent anti-DHBV activities in vivo. The cell-permeable antibody against the virus core antigen may be developed as a novel treatment for patients with hepadnavirus infections.

Indexed as

Disease Models, AnimalAnimalsAntibodies, MonoclonalAntiviral AgentsDNA, ViralDose-Response Relationship, DrugDucksFemaleHepatitis B virusMicrobial Sensitivity TestsStructure-Activity RelationshipViral Core ProteinsVirus ReplicationAntibodies, MonoclonalAntiviral AgentsDNA, ViralViral Core Proteins

Identifiers

PMID28383135
PMCPMC5481659
OpenAlexW2605145059

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.